Provider review
PepScribe review
Names four 503A pharmacies directly — but only a $159-$548 range is published.
PepScribe's own /pharmacy-partners page names four pharmacies by name ("licensed 503A pharmacies, not 503B outsourcing facilities"), a real, specific disclosure — but its homepage and FAQ both publish only a $159-$548 range across every therapy and dose, with no page anywhere breaking out what tirzepatide, semaglutide, or sermorelin specifically cost.
Transparency scorecard
3 of 4 disclosed openly
What PepScribe discloses about itself, read from its own pages — not estimated.
Pharmacy named & regulated
Disclosed
Names its compounding pharmacy and states a federal regulatory category (503A/503B), sourced to its own site.
State coverage published
Not disclosed
Publishes no state coverage list — availability is something you learn during signup.
A real price is published
Disclosed
A real dollar figure is published on its own site, not estimated.
No hidden commitment trap
Disclosed
The advertised price is the ongoing price — no prepay or auto-refill required to unlock it.
This review's stake, stated plainly — some of the outbound links on this site are affiliate links; start a program through one and we may earn a commission at no extra cost to you. Straight about the rest, too: the write-ups say what each provider is actually worth, and a commission does not change a word of them. Full disclosure here.
On this page
What it actually costs
What they advertise
PepScribe's own homepage and FAQ state identically, "$159 to $548 depending on the therapy and your prescribed dose" — confirmed present verbatim on both pages today.
What you actually pay, month to month
No per-compound flat or floor rate is published anywhere reachable — /pricing and /tirzepatide both 404. The $159-$548 figure is a range across all therapies and doses, not a specific tirzepatide, semaglutide, or sermorelin number.
Money you will meet later
- A quarterly prepay option ("from $447/quarter... up to 20% savings when prepaid") is offered separately and clearly labeled a discount off the monthly rate, not the standing price itself.
Checked live on PepScribe's own site at https://www.pepscribe.com/faq in August 2026. Prices change without notice — confirm before you buy. Every figure here was read off PepScribe's own public pages on the date shown, not from a third-party comparison table.
The bottom line
PepScribe (pepscribe.com, legal entity PepScribe LLC) is a real, one-month-old telehealth company selling compounded tirzepatide, compounded semaglutide, and compounded sermorelin, with clinical services delivered by an independent telehealth partner, Ola Digital Health. Its pharmacy disclosure is genuinely strong — four named 503A pharmacies, more specific than most peers on this roster. The gap is pricing specificity: only a $159-$548 range is published anywhere, with no per-compound breakdown reachable without starting the intake.
PepScribe appears on our sermorelin provider ranking, our tirzepatide provider ranking and our semaglutide provider ranking. Nothing on this page is a performance claim.
Who it is for, and who it is not
A good fit if
- You want a real, named-pharmacy 503A disclosure — four pharmacies named directly, not a category claim alone.
- You want "No contracts, no cancellation fees, no retention calls," stated plainly on its own site.
- You're comfortable starting a free intake to learn your own specific price before committing to anything.
Look elsewhere if
- You want to know what tirzepatide, semaglutide, or sermorelin specifically cost before starting an intake — only an undifferentiated $159-$548 range across every therapy is published anywhere.
- You want an explicit states-served claim — its own FAQ only says clinicians are "licensed in your state," no list or all-50 claim.
- You want a company with any review history — it launched via wire press release on 2026-07-02, one month before this review.
What is included
The cheapest headline number in this category is often the one with the least attached to it. Here is what PepScribe bundles in, and what it does not.
Clinician consult
Included
— a clinical intake and provider review is required before a prescription is issued, per its own site.
Bloodwork / labs
Not stated on the pages checked.
Follow-ups and dose changes
Not itemized on the pages checked.
Human support
No dietitian, nurse, or structured coaching program is named…
anywhere on the pages checked.
Injection supplies
Not itemized beyond the medication itself on the pages checked.
Shipping
Not itemized on the pages checked.
Who fills it, and who's watching
The pharmacy
503A. Its own /pharmacy-partners page names FOUR pharmacies directly (Pharmacy Innovations, Sweetgrass Pharmacy & Compounding, Absolute Pharmacy, Striker Pharmacy) and states, unhedged, "licensed 503A pharmacies, not 503B outsourcing facilities."
Oversight
Included — a clinical intake and provider review is required before a prescription is issued, per its own site. Not itemized on the pages checked.
Compounded peptides are not FDA-approved products, and a 503A pharmacy compounds for a named patient while a 503B outsourcing facility manufactures in batches under CGMP. Neither is a quality guarantee on its own — a named facility is simply a fact you can check, and an unnamed “partner pharmacy network” is not.
Where you can get it
Not published. Its own FAQ states only that clinicians are "licensed in your state" — no all-50 or explicit list claim was found anywhere checked.
The honest cons
The part they would rather you skipped
PepScribe's own homepage and FAQ publish only a $159-$548 range across every therapy and dose, with no page anywhere — not even a specific compound page — breaking out what tirzepatide, semaglutide, or sermorelin actually cost on its own. A prospective patient cannot learn a real, specific price without starting the (free) intake assessment first.
- No page anywhere publishes a compound-specific price — only an undifferentiated $159-$548 range across all therapies.
- No states-served or states-excluded list is published anywhere checked.
- The company is one month old at time of writing, with no independent review history yet.
None of this is unique to PepScribe — the whole category shares it.
How it compares
The providers we rank on our sermorelin provider ranking — the most specific board PepScribe sits on — in the order that board ranks them. It sells into other categories too; see the boards listed above under the bottom line.
- TRTelos RxA specific, sourced state-exclusion list — next to an unconfirmed "compare" price.
- Strut HealthAn FDA warning letter over labeling, plus an auto-refill price on every product.
- MAMangoRxA flat, "price locked in" semaglutide product — its pharmacy is described, not named.
- SRSynergy RxSells no GLP-1 at all — and its own legal terms undercut its "all 50 states" marketing.
- EHEOS HealthNames five 503A pharmacies — but its own legal pages disagree on HIPAA.
- PLPlexusDxPriciest starting-price seller; the only one admitting it's not FDA-approved.
- PRPreventiveMDShows every price tier in one table — but its own headline is the cheapest one.
- BHBionomy HealthA named fulfillment pharmacy has its own real FDA warning letter.
35 more providers rank on our sermorelin provider ranking — see the full ranking. Every provider we review →
Read this before you buy
A provider comparison is half the decision. The other half is whether the compound does anything for you at all — and whether it is allowed where you compete. Growth-hormone secretagogues are banned in tested sport, year-round, and a prescription does not change that.
Facts on this page reflect PepScribe's own public disclosures when we last checked them, in August 2026. Prices and terms change without notice — confirm on PepScribe's site before you buy. Provider names and logos on this page identify the company under review; their use does not imply endorsement, sponsorship or affiliation. This page is informational and not medical advice; compounded peptides are not FDA-approved, and growth-hormone secretagogues are banned in tested sport year-round. See our disclosure and editorial policy.